208 related articles for article (PubMed ID: 35378840)
1. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
[TBL] [Abstract][Full Text] [Related]
2. Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?
Pan YT; Lin YP; Yen HK; Yen HH; Huang CC; Hsieh HC; Janssen S; Hu MH; Lin WH; Groot OQ
Clin Orthop Relat Res; 2024 Mar; ():. PubMed ID: 38517402
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer.
Li W; Wu X; Yu H; Zhu Z; Li W; Huang X
Clin Med Insights Oncol; 2023; 17():11795549231182266. PubMed ID: 37448470
[TBL] [Abstract][Full Text] [Related]
5. Health resource utilization associated with skeletal-related events: results from a retrospective European study.
Body JJ; Pereira J; Sleeboom H; Maniadakis N; Terpos E; Acklin YP; Finek J; Gunther O; Hechmati G; Mossman T; Costa L; Rogowski W; Nahi H; von Moos R
Eur J Health Econ; 2016 Jul; 17(6):711-21. PubMed ID: 26253584
[TBL] [Abstract][Full Text] [Related]
6. Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study.
Mizuta K; Oshiro H; Katsuki R; Tsuha Y; Aoki Y; Tome Y; Nishida K
BMC Cancer; 2023 Oct; 23(1):999. PubMed ID: 37853409
[TBL] [Abstract][Full Text] [Related]
7. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland.
Lothgren M; Ribnicsek E; Schmidt L; Habacher W; Lundkvist J; Pfeil AM; Biteeva I; Vrouchou P; Bracco A
Eur J Hosp Pharm; 2013 Aug; 20(4):227-231. PubMed ID: 23888248
[TBL] [Abstract][Full Text] [Related]
8. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
von Moos R; Body JJ; Rider A; de Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2018 Jun; 11():1-9. PubMed ID: 29892519
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
[TBL] [Abstract][Full Text] [Related]
11. Towards proactive palliative care in oncology: developing an explainable EHR-based machine learning model for mortality risk prediction.
Zhuang Q; Zhang AY; Cong RSTY; Yang GM; Neo PSH; Tan DS; Chua ML; Tan IB; Wong FY; Eng Hock Ong M; Shao Wei Lam S; Liu N
BMC Palliat Care; 2024 May; 23(1):124. PubMed ID: 38769564
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Bone Metastases and Skeletal-Related Events in Patients With
Brouns AJWM; van Veelen A; Veerman GDM; Steendam C; Dursun S; van der Leest C; Croes S; Dingemans AC; Hendriks LEL
JTO Clin Res Rep; 2023 May; 4(5):100513. PubMed ID: 37168878
[TBL] [Abstract][Full Text] [Related]
13. Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Phillips WJ; Saad F; Leigh J; Jooya A; Webber C; Morgan S; MacRae R; Bourque JM; Tanuseputro P; Ong M
Oncologist; 2024 Mar; ():. PubMed ID: 38527096
[TBL] [Abstract][Full Text] [Related]
14. Review of Bone Modifying Agents in Metastatic Breast Cancer.
Raghu Subramanian C; Talluri S; Mullangi S; Lekkala MR; Moftakhar B
Cureus; 2021 Feb; 13(2):e13332. PubMed ID: 33738175
[TBL] [Abstract][Full Text] [Related]
15. Explainable machine learning model for predicting skeletal muscle loss during surgery and adjuvant chemotherapy in ovarian cancer.
Hsu WH; Ko AT; Weng CS; Chang CL; Jan YT; Lin JB; Chien HJ; Lin WC; Sun FJ; Wu KP; Lee J
J Cachexia Sarcopenia Muscle; 2023 Oct; 14(5):2044-2053. PubMed ID: 37435785
[TBL] [Abstract][Full Text] [Related]
16. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.
Aapro M; Saad F
Ther Adv Urol; 2012 Apr; 4(2):85-101. PubMed ID: 22496711
[TBL] [Abstract][Full Text] [Related]
17. Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study.
Sato S; Tomitori H; Okawa A; Akano K
Int J Clin Oncol; 2023 Sep; 28(9):1227-1235. PubMed ID: 37314600
[TBL] [Abstract][Full Text] [Related]
18. Predicting Skeletal-related Events Using SINS.
Nakanishi K; Hijikata Y; Uchino K; Sugimoto Y; Iba H; Watanabe S; Mitani S
Spine (Phila Pa 1976); 2024 Mar; ():. PubMed ID: 38475677
[TBL] [Abstract][Full Text] [Related]
19. Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma.
Parrondo RD; Sher T
Onco Targets Ther; 2019; 12():8467-8478. PubMed ID: 31686861
[TBL] [Abstract][Full Text] [Related]
20. Incidence of skeletal-related events in patients with Ewing sarcoma: An observational retrospective study in Japan.
Aiba H; Kojima Y; Shimoi T; Sudo K; Yazaki S; Imai T; Yoshida A; Iwata S; Kobayashi E; Kawai A; Arakawa A; Ogawa C; Kimura H; Yonemori K
Cancer Med; 2024 Mar; 13(5):e7060. PubMed ID: 38466026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
